A multi-center, single-arm, open-label study to evaluate tolerability, safety, and efficacy of topical MOB015B solution in the treatment of mild to moderate distal subungual onychomycosis (DSO) in subjects aged 6-17 years
Latest Information Update: 10 Sep 2024
At a glance
- Drugs Terbinafine (Primary)
- Indications Onychomycosis
- Focus Therapeutic Use
- Sponsors Moberg Pharma
Most Recent Events
- 04 May 2023 New trial record